For research and educational purposes only. Not medical advice.
Exenatide Reference
Educational, not medical advice reference for Exenatide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also known…
Reference summary
Exenatide was the first GLP-1 receptor agonist approved in the US and is one of the longest-running safety-evidence GLP-1s. pepSmart surfaces label-reference schedules only.
- Categories
- GLP-1, Fat Loss
- Aliases
- Byetta, Bydureon BCise, Exendin-4 analog
- Evidence posture
- human
- Regulatory status
- FDA-approved exenatide label references exist for Byetta (twice-daily, first approved 2005) and Bydureon BCise (once-weekly extended-release). Both are approved as adjuncts to diet and exercise in adults with type 2 diabetes; they are not approved as weight-loss therapies.
- Content review status
- label verified